For our final spotlight blog, we are delighted to feature our Biotherapeutics Working Group, which will have their last get-together of the year today. This working group originally focused on biosimilars and related regulatory challenges, but it eventually expanded to include all biotherapeutics, including innovative therapeutics, for example antibodies, and how they are regulated. Biologic ..read more

Our spotlight series is turning to EBE’s Innovation and Funding Models Working Group, which is meeting at EBE headquarters today. The Innovation and Funding Models Working Group aims to ensure the best entrepreneurial conditions for the biopharmaceutical industry in Europe. Its initiatives are, for example, designed to engage stakeholders around the funding of biopharmaceutical innovation ..read more

Continuing with our spotlight series, the European Biopharmaceutical Enterprises (EBE) is featuring its Advanced Therapies Working Group, a joint working group with EFPIA, which will be meeting today. The Advanced Therapies Working Group is involved with some of the most exciting aspects of the biopharmaceutical industry from CAR-T cell therapies to gene therapies. Its goal ..read more

The European Biomanufacturing Enterprises (EBE) continues its spotlight series with a feature on our Biomanufacturing Working Group, which is meeting at the EBE headquarters today. The objective of the working group is to elevate biotech manufacturing in the technical and quality arena and foster an enabling regulatory environment for the manufacturing of high-quality biological medicines ..read more

By Barbara Freischem, Executive Director Last week, I had the privilege of speaking at a roundtable discussion, organised by Johnson&Johnson and EurActiv as part of the European Biotech Week, to address the important question: is Europe attractive for live science investments? Europe certainly has great science and academia; we’re well-regulated and adapting to new challenges ..read more

Brussels is back in full swing and so are the European Biopharmaceutical Enterprises’ (EBE) Working Groups! Today, we are kicking off a new spotlight series featuring each of EBE’s working groups, starting with the one focusing on personalised medicine (PM), which will be meeting today. The Personalised Medicine Working Group (PMWG), which is now a ..read more

At European Biopharmaceutical Enterprises (EBE), one of our top priorities has always been to advocate for better access to innovative personalised medicine to help deliver tangible health improvements for EU citizens. That’s why today we are calling on EU Member States to implement five new policy recommendations for personalised medicine from coherent prioritisation of personalised ..read more

The European Biopharmaceutical Enterprises (EBE), represented by myself, is back in Brussels after an action-packed week at the BIO2018 conference in Boston. BIO2018 was a milestone event, as it marked 25 years of BIO innovation and set the official Guinness world record for the largest business partnering event. What did BIO2018 mean for EBE? The ..read more

CBG-MEB's Marcel Hoefnagel presenting on CAR-T cell therapy Today the CASSS CMC Strategy Forum Europe 2018 meeting in Noordwijk, the Netherlands, concluded three days of productive discussions. European Biopharmaceutical Enterprises (EBE) is delighted to have opened this meeting of biomanufacturing and CMC specialists from around the world with a half day satellite forum. Biomanufacturing ..read more

The European Biopharmaceutical Enterprises (EBE) has just submitted comments, prepared by its Innovation & Funding Models Working Group, to the European Commission on its review of how small to medium-sized enterprises (SMEs) are defined. This is a welcome opportunity for the biopharmaceutical industry, considering that the SME designation provides our businesses with access to ..read more